Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 141-150 of 220 for Multiple Myeloma

Edit search filters
  1. A Study to Evaluate APG2575 Combined with Novel Therapeutic Regimens To Treat Subjects with Relapsed or Refractory Multiple Myeloma and Immunoglobulin Light Chain Amyloidosis

    Jacksonville, FL, Scottsdale/Phoenix, AZ

  2. Panobinostat and Everolimus in Treating Patients with Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma

    Scottsdale/Phoenix, AZ, Rochester, MN

  3. A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

    Jacksonville, FL, Rochester, MN

  4. A Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Rochester, MN

  6. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effectiveness of AMG 397 in Subjects With Multiple Myeloma, NHL, and AML

    Jacksonville, FL

  7. A Study to Evaluate ION251 to Treat Patients with Relapsed/Refractory Multiple Myleoma

    Scottsdale/Phoenix, AZ, Rochester, MN, Jacksonville, FL

  8. A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma

    Jacksonville, FL

  9. A Study to Evaluate Lenalidomide and Dexamethasone, with or without Daratumumab, in Treating High-Risk Smoldering Myeloma Patients

    Albert Lea, MN, Eau Claire, WI, Rochester, MN

  10. Long-Term Study of Participants Previously with Ciltacabtagene Autoleucel

    Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer